[{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","commit":"08f191a505","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty more approved products","file":"src/data/spikes/multiple-myeloma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Elranatamab\" }]"}]},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/multiple-myeloma.ts","type":"changed","fields":[{"field":"tldr","before":"\"Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.\"","after":"\"Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.\""}]},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","commit":"2997dc2520","date":"2026-09-08","author":"Jude Gomila","message":"Deep cancer spikes: DLBCL, multiple myeloma, Hodgkin lymphoma, sarcoma, neuroblastoma (135 new entities with structured outcomes, dosing, to","file":"src/data/spikes/multiple-myeloma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]